Also trades as: 200028.SZ (SHZ) · $vol 0M
000028.SZ SHZ
China National Accord Medicines Corporation Ltd.
1W: -1.2%
1M: -1.3%
3M: -0.5%
YTD: -25.0%
1Y: -23.1%
3Y: -45.2%
5Y: -28.5%
¥19.66 ($2.93)
+0.29 (+1.50%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$73.4B
-1.3% ▼
5Y CAGR: +4.2%
Gross Profit
$73.4B
+795.5% ▲
5Y CAGR: +59.9%
Operating Income
$1.5B
+163.8% ▲
5Y CAGR: -6.9%
Net Income
$1.1B
+76.8% ▲
5Y CAGR: -4.1%
EPS (Diluted)
$2.04
+77.4% ▲
5Y CAGR: -4.1%
EBITDA
$1.5B
-12.9% ▼
5Y CAGR: -6.4%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $68.4B | $73.4B | $75.5B | $74.4B | $73.4B |
| YoY Growth | +14.6% | +7.4% | +2.8% | -1.5% | -1.3% |
| Cost of Revenue | $60.4B | $64.6B | $66.5B | $66.2B | $0 |
| Gross Profit | $8.0B | $8.9B | $9.0B | $8.2B | $73.4B |
| Gross Margin | 11.7% | 12.1% | 11.9% | 11.0% | 100.0% |
| R&D Expenses | $8M | $9M | $27M | $25M | $0 |
| SG&A Expenses | $5.5B | $6.1B | $6.2B | $6.2B | $0 |
| Operating Expenses | $6.0B | $6.6B | $6.5B | $7.6B | $71.9B |
| Operating Income | $2.0B | $2.3B | $2.5B | $573M | $1.5B |
| Operating Margin | 2.9% | 3.1% | 3.3% | 0.8% | 2.1% |
| Interest Expense | $288M | $262M | $285M | $296M | $0 |
| Income Before Tax | $2.0B | $2.3B | $2.5B | $575M | $1.5B |
| Tax Expense | $447M | $539M | $515M | $338M | $0 |
| Net Income | $1.3B | $1.5B | $1.6B | $642M | $1.1B |
| Net Margin | 2.0% | 2.0% | 2.1% | 0.9% | 1.5% |
| EPS (Diluted) | $2.40 | $2.67 | $2.87 | $1.15 | $2.04 |
| EBITDA | $2.2B | $2.5B | $3.8B | $1.7B | $1.5B |
| Shares Outstanding | 557M | 557M | 557M | 559M | 557M |